Urokinase is required for the formation of mactinin, an alpha-actinin fragment that promotes monocyte/macrophage maturation.
We have previously shown that lysates from HL-60 myeloid leukemia cells or from peripheral blood monocytes are able to degrade alpha-actinin to form a 31-kDa amino-terminal fragment with monocyte/macrophage maturation promoting activity. In contrast, intact alpha-actinin, which is a 100-kDa actin-binding protein, has no differentiating activity. The aim of this study was to investigate the enzyme responsible for the degradation of alpha-actinin to form this fragment, named mactinin. The ability of cell lysates to degrade [125I]alpha-actinin in the presence of various enzyme inhibitors, including inhibitors of metalloproteinases, cysteine proteinases, and serine proteases, was measured. Phenylmethylsulfonyl fluoride (PMSF) was the only inhibitor able to prevent formation of mactinin by cell lysate degradation of alpha-actinin, suggesting that a serine protease is responsible for the digestion. Of the various serine proteases tested (thrombin, plasmin, and urokinase), only urokinase was able to produce a 31-kDa band. The urokinase-generated 31-kDa band promoted maturation in HL-60 cells. Amiloride, a specific inhibitor of urokinase, inhibited production of the 31-kDa alpha-actinin fragment by HL-60 cell lysates. For in vivo tests, inflammatory fluid (from bronchoalvelolar lavage) was collected from uPA (urokinase) knockout mice and their wild-type counterparts after intratracheal challenge with Pneumocystis carinii. Although most (6 of 8) wild-type mice had mactinin in their inflammatory fluid samples, none (0 of 8) of the uPA knockout mice had mactinin present (P<0.01). These results demonstrate that urokinase is necessary and sufficient for the formation of the monocyte/macrophage maturation promoting fragment, mactinin, in vitro and in vivo. These findings support the role of urokinase in the regulation of monocyte/macrophage functions, such as that occurring in inflammatory reactions.
Veterans Affairs Medical Center, Minneapolis, MN, USA. sharon.luikart@med.va.gov
Sharon
S
Luikart
Mohammed
M
Masri
Dan
D
Wahl
Tim
T
Hinkel
James M
JM
Beck
Margaret R
MR
Gyetko
Pankaj
P
Gupta
Theodore
T
Oegema
D000185:Actinin / Q000096:biosynthesis / Q000502:physiology*; D000584:Amiloride / Q000494:pharmacology; D000818:Animals; D016922:Cellular Senescence; D004777:Environment; D018922:HL-60 Cells; D006801:Humans; D008264:Macrophages / Q000187:drug effects / Q000502:physiology*; D051379:Mice; D018345:Mice, Knockout; D008970:Molecular Weight; D009000:Monocytes / Q000187:drug effects / Q000502:physiology*; D010446:Peptide Fragments; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology; D014105:Tosyl Compounds / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*
D010446:Peptide Fragments; D015842:Serine Proteinase Inhibitors; D014105:Tosyl Compounds; C485291:mactinin, human; D000185:Actinin; C003614:4-toluenesulfonyl fluoride; D000584:Amiloride; D014568:Urokinase-Type Plasminogen Activator